Explanipedia

Atorvastatin versus Placebo in ICU Patients with COVID-19: Ninety-day Results of the INSPIRATION-S Trial Open

Azita H. Talasaz, Parham Sadeghipour, Hooman Bakhshandeh, Babak Sharif-Kashani, Farid Rashidi , et al. · 2023

Background In the INSPIRATION-S trial, atorvastatin versus placebo was associated with a nonsignificant 16% reduction in 30-day composite of venous/arterial thrombosis or death in intensive care unit (ICU) patients with COVID-19. Thrombo-i…

Evaluating the role of intravenous pentoxifylline administration on primary percutaneous coronary intervention success rate in patients with ST-elevation myocardial infarction (PENTOS-PCI) Open

Hessam Kakavand, Seyedmohammad Saadatagah, Mohammadreza Naderian, Maryam Aghakouchakzadeh, Arash Jalali , et al. · 2023

Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial Open

Parham Sadeghipour, Behnood Bikdeli, Azita H. Talasaz, Babak Sharif-Kashani, Farid Rashidi , et al. · 2022

Objective To assess the effect of statin treatment versus placebo on clinical outcomes in patients with covid-19 admitted to the intensive care unit (ICU). Design INSPIRATION/INSPIRATION-S was a multicenter, randomized controlled trial wit…

Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19 Open

Azita H. Talasaz, Parham Sadeghipour, Maryam Aghakouchakzadeh, Isaac Dreyfus, Hessam Kakavand , et al. · 2021

Use of novel antithrombotic agents for COVID‐19: Systematic summary of ongoing randomized controlled trials Open

Azita H. Talasaz, Parham Sadeghipour, Maryam Aghakouchakzadeh, Hessam Kakavand, Hamid Ariannejad , et al. · 2021

Lipid-Modulating Agents for Prevention or Treatment of COVID-19 in Randomized Trials Open

Azita H. Talasaz, Parham Sadeghipour, Maryam Aghakouchakzadeh, Isaac Dreyfus, Hessam Kakavand , et al. · 2021

Coronavirus disease 2019 (COVID-19) is associated with systemic inflammation, endothelial activation, and multi-organ manifestations. Lipid modulating agents may be useful in treating patients with COVID-19. They may inhibit viral entry by…

Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial Open

Behnood Bikdeli, Azita H. Talasaz, Farid Rashidi, Hooman Bakhshandeh, Farnaz Rafiee , et al. · 2021

Background Thrombotic complications are considered among the main extrapulmonary manifestations of coronavirus disease 2019 (COVID-19). The optimal type and duration of prophylactic antithrombotic therapy in these patients remain unknown. …

Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19 Open

Azita H. Talasaz, Parham Sadeghipour, Hessam Kakavand, Maryam Aghakouchakzadeh, Elaheh Kordzadeh-Kermani , et al. · 2021

Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit Open

Saeideh Mazloomzadeh, Shiva Khaleghparast, Behshid Ghadrdoost, Mostafa Mousavizadeh, Mohammad Reza Baay , et al. · 2021

ClinicalTrials.gov Identifier: NCT04486508.

Comparing the Effects of Acceptance and Commitment Therapy and Metacognitive Therapy on Blood Pressure in Hemodialysis Patients Open

Samira Haddadi, Saied Malihialzackerini, Ramin Tajbakhsh, Mansoureh Tajvidi, Hessam Kakavand · 2021

Background and Objectives: Dialysis patients encounter numerous psychological distress, aggravating their psycho-social problems. Currently, the third wave of psychological treatment has surpassed other treatments in solving the problems o…

Antithrombotic Therapy in COVID-19: Systematic Summary of Ongoing or Completed Randomized Trials Open

Azita H. Talasaz, Parham Sadeghipour, Hessam Kakavand, Maryam Aghakouchakzadeh, Elaheh Kordzadeh-Kermani , et al. · 2021

Endothelial injury and microvascular/macrovascular thrombosis are common pathophysiologic features of coronavirus disease-2019 (COVID-19). However, the optimal thromboprophylactic regimens remain unknown across the spectrum of illness seve…

Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective Open

Azita H. Talasaz, Hessam Kakavand, Benjamín Van Tassell, Maryam Aghakouchakzadeh, Parham Sadeghipour , et al. · 2020

Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19) Open

Dave L. Dixon, Benjamín Van Tassell, Alessandra Vecchié, Aldo Bonaventura, Azita H. Talasaz , et al. · 2020

A novel betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread rapidly across the globe since December 2019. Coronavirus disease 2019 (COVID-19) has a significantly higher mortality rate than seasonal inf…

Hessam Kakavand YOU? Author Swipe